Login to Your Account



Clinic Roundup


Tuesday, September 11, 2012
• Palatin Technologies Inc., of Cranbury, N.J., said the last patient completed treatment in its Phase IIb study testing melanocortin agonist bremelanotide in female sexual dysfunction, and top-line data are expected in the first half of next quarter. The study enrolled about 400 premenopausal women, diagnosed with female sexual arousal disorder, hypoactive sexual desire disorder or both, and is designed to test subcutaneous doses of the drug intended for on-demand use.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription